CurrentEndo
Get Weekly

CurrentEndo coverage · page 48 of 55

Diabetes, Obesity and Metabolism

Briefs 1,881–1,920 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial

    Secondary analysisDiabetes in pregnancy

  2. Diabetes Obes Metab

    Long‐term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong

    Cohort studyComplications

  3. Diabetes Obes Metab

    Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins

    Randomized controlled trialT1D

  4. Diabetes Obes Metab

    Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study

    Cohort studyT2D & other

  5. Diabetes Obes Metab

    A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy

    Randomized controlled trialT2D & other

  6. Diabetes Obes Metab

    Telehealth use and its impact on clinical outcomes in patients with type 2 diabetes during the COVID ‐19 pandemic

    Cohort studyT2D & other

  7. Diabetes Obes Metab

    Derivation and independent validation of kidneyintelX .dkd: A prognostic test for the assessment of diabetic kidney disease progression

    Diagnostic or prognostic studyComplications

  8. Diabetes Obes Metab

    Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study

    Randomized controlled trialComplications

  9. Diabetes Obes Metab

    Diabetes foot complications and standardized mortality rate in type 2 diabetes

    Cohort studyComplications

  10. Diabetes Obes Metab

    Intermittently scanned continuous glucose monitoring and hypoglycaemia awareness in drivers with diabetes: Insights from the Association of British Clinical Diabetologists Nationwide audit

    Research articleTechnology

  11. Diabetes Obes Metab

    The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months

    Cohort studyT2D & other

  12. Diabetes Obes Metab

    Severe (level 3) hypoglycaemia occurrence in a real‐world cohort of adults with type 1 or 2 diabetes mellitus ( iNPHORM , United States)

    Cohort studyComplications

  13. Diabetes Obes Metab

    Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials

    Meta-analysisObesity

  14. Diabetes Obes Metab

    The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes ( TROPHIES ): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes

    Cohort studyT2D & other

  15. Diabetes Obes Metab

    Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial

    Secondary analysisObesity

  16. Diabetes Obes Metab

    Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 2 diabetes

    Research articleT2D & other

  17. Diabetes Obes Metab

    L ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German–Austrian diabetes registry

    Cross-sectional studyT2D & other

  18. Diabetes Obes Metab

    Metformin restores prohormone processing enzymes and normalizes aberrations in secretion of proinsulin and insulin in palmitate‐exposed human islets

    Mechanistic studyT2D & other

  19. Diabetes Obes Metab

    Association between weight loss and health care resource utilization in adults living with obesity: Evidence from a UK primary care database

    Cohort studyObesity

  20. Diabetes Obes Metab

    The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Secondary analysisT2D & other

  21. Diabetes Obes Metab

    Efficacy and safety of once‐weekly versus once‐daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta‐analysis

    Meta-analysisT2D & other

  22. Diabetes Obes Metab

    Younger patients and low c‐peptide immunoreactivity index but not nutritional states affect fasting blood ketone levels in Japanese with type 1 diabetes after sodium‐glucose cotransporter 2 inhibitor administration

    Cohort studyT1D

  23. Diabetes Obes Metab

    No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)

    Randomized controlled trialT2D & other

  24. Diabetes Obes Metab

    Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial

    Randomized controlled trialT2D & other

  25. Diabetes Obes Metab

    The rest‐activity rhythm, genetic susceptibility and risk of type 2 diabetes: A prospective study in UK Biobank

    Cohort studyT2D & other

  26. Diabetes Obes Metab

    Beta‐cell death and dysfunction drives hyperglycaemia in organ donors

    Cohort study

  27. Diabetes Obes Metab

    Comparison of clinical efficacy and safety of weekly glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel‐group, multicentre, open‐label trial ( COMING study)

    Randomized controlled trialT2D & other

  28. Diabetes Obes Metab

    Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials

    Meta-analysisT2D & other

  29. Diabetes Obes Metab

    Association between glycated haemoglobin and the risk of chronic obstructive pulmonary disease: A prospective cohort study in UK biobank

    Cohort study

  30. Diabetes Obes Metab

    Interrupting prolonged sitting with frequent short bouts of light‐intensity activity in people with type 1 diabetes improves glycaemic control without increasing hypoglycaemia: The SIT‐LESS randomised controlled trial

    Randomized controlled trialT1D

  31. Diabetes Obes Metab

    Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY )

    Randomized controlled trialT2D & other

  32. Diabetes Obes Metab

    Safety and effectiveness of dulaglutide in Chinese adults with type 2 diabetes mellitus in a real‐world setting: A prospective, observational post‐marketing study

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    A J‐shaped relationship between ketones and the risk of diabetic kidney disease in patients with type 2 diabetes: New insights from a cross‐sectional study

    Cross-sectional studyComplications

  34. Diabetes Obes Metab

    Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co‐expression network analysis and machine learning techniques

    Case-control studyComplications

  35. Diabetes Obes Metab

    A multicomponent health care intervention is associated with improved glycaemic control in subjects with poorly controlled type 2 diabetes compared with routine care: The INTEGRA study

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker

    Research articleT2D & other

  37. Diabetes Obes Metab

    Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole‐body 18 F‐fluorodeoxyglucose‐positron emission tomography

    Cohort studyT2D & other

  38. Diabetes Obes Metab

    Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults

    Cross-sectional studyObesity

  39. Diabetes Obes Metab

    Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

    Randomized controlled trialT2D & other

  40. Diabetes Obes Metab

    A 1‐year pilot study of intralymphatic injections of GAD‐alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes

    Research articleT1D

All 2,200 Briefs in ExploreShowing Briefs 1,881–1,920 of 2,200, newest first